首頁 › 骨髓增生異常症候群 › 麻薩諸塞 › Boston
Boston, MA 的 骨髓增生異常症候群 臨床試驗
19 項針對 骨髓增生異常症候群 的研究正在 Boston（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
招募中2 期
- Tufts Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
招募中2 期
- Tufts Medical Center, Boston
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
招募中1 期
- Dana-Farber Cancer Institute, Boston
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
招募中1/2 期
- Dana-Farber Cancer Institute, Boston
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
招募中3 期
- Massachusetts General Hospital, Boston
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
招募中1/2 期
- Dana-Farber Cancer Institute, Boston
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
招募中1 期歡迎健康志工
- Brigham and Women's Hospital, Boston
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
招募中1 期
- Boston Children's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
招募中1 期
- Dana-Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
招募中1 期
- Dana Farber Cancer Institute, Boston
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
招募中觀察性研究
- Dana-Farber Cancer Institute, Boston
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
招募中2/3 期
- Dana-Farber Cancer Institute, Boston
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
招募中1/2 期
- Massachusetts General Hospital, Boston
Venetoclax Basket Trial for High Risk Hematologic Malignancies
招募中1 期
- Dana-Farber Cancer Institute, Boston
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
招募中2 期歡迎健康志工
- DFCI/BWH Brigham and Women's Hospital, Boston
IS-free Treg HaploHCT
招募中1 期
- Dana Farber Cancer Institute, Boston
HEME Home Transfusion Program
招募中
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Study of REM-422 in Patients With AML or Higher Risk MDS
招募中1 期
- Massachusetts General Hospital, Boston
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
招募中1 期
- Dana-Farber Cancer Institute, Boston
其他城市的 骨髓增生異常症候群 試驗
- Houston, TX43 項研究
- Baldwin Park, CA26 項研究
- New York City, NY21 項研究
- Seattle, WA21 項研究
- Washington, DC20 項研究
- Tampa, FL19 項研究
- Miami, FL17 項研究
- Durham, NC14 項研究
- Columbus, OH14 項研究
- St. Louis, MO13 項研究
- Atlanta, GA13 項研究
- Chicago, IL13 項研究
Boston 的其他研究
- 乳癌112 項研究
- 非小細胞肺癌90 項研究
- 癌症（所有類型）85 項研究
- 轉移性癌症63 項研究
- 大腸直腸癌63 項研究
- 肺癌62 項研究
- 卵巢癌61 項研究
- 前列腺癌59 項研究
- 憂鬱症52 項研究
- 子宮內膜癌50 項研究
- 心臟衰竭44 項研究
- 急性髓系白血病44 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。